Clinical Trials Browser

Endometrial Adenocarcinoma × Trastuzumab × Gynecologic × Clear all

NCT00006089 2019-07-31

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Completed

Endometrial Adenocarcinoma